Bicycle Therapeutics Ltd (BCYC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bicycle Therapeutics Ltd (BCYC) has a cash flow conversion efficiency ratio of -0.115x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-71.17 Million) by net assets ($618.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Bicycle Therapeutics Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Bicycle Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Bicycle Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bicycle Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bicycle Therapeutics Ltd ranked by their cash flow conversion efficiency. See Bicycle Therapeutics Ltd cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Netfonds AG
XETRA:NF4
|
0.058x |
|
AN2 Therapeutics Inc
NASDAQ:ANTX
|
-0.092x |
|
United Paper Public Company Limited
BK:UTP
|
0.036x |
|
Ador Welding Limited
NSE:ADORWELD
|
0.013x |
|
Groupe Sfpi
PA:SFPI
|
0.132x |
|
Isu Chemical Co Ltd
KO:005950
|
0.147x |
|
CoreCard Corp
NYSE:CCRD
|
0.112x |
|
Able C&C
KO:078520
|
0.077x |
Annual Cash Flow Conversion Efficiency for Bicycle Therapeutics Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Bicycle Therapeutics Ltd from 2016 to 2024. View Bicycle Therapeutics Ltd stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $793.06 Million | $-164.72 Million | -0.208x | -27.08% |
| 2023-12-31 | $370.93 Million | $-60.63 Million | -0.163x | +48.60% |
| 2022-12-31 | $270.78 Million | $-86.11 Million | -0.318x | -644.30% |
| 2021-12-31 | $346.25 Million | $-14.79 Million | -0.043x | +77.07% |
| 2020-12-31 | $95.46 Million | $-17.79 Million | -0.186x | +39.30% |
| 2019-12-31 | $93.20 Million | $-28.61 Million | -0.307x | -182.21% |
| 2018-12-31 | $-69.83 Million | $-26.08 Million | 0.373x | +1145.36% |
| 2017-12-31 | $-47.18 Million | $-1.42 Million | 0.030x | +102.14% |
| 2016-12-31 | $8.02 Million | $-11.27 Million | -1.404x | -- |
About Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT552… Read more